Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2025, Vol. 30 ›› Issue (8): 1112-1121.doi: 10.12092/j.issn.1009-2501.2025.08.013
Previous Articles Next Articles
WEI Xiaocheng, LI Xinrong, HE Jungang, LI Xu, QIANG Zhengze, WANG Yan, WANG Mingwei, LI Chengyi
Received:2024-06-18
Revised:2024-12-09
Online:2025-08-26
Published:2025-08-12
CLC Number:
WEI Xiaocheng, LI Xinrong, HE Jungang, LI Xu, QIANG Zhengze, WANG Yan, WANG Mingwei, LI Chengyi. Research progress on antitumor effects of Hedysari radix and active components[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1112-1121.
| [1] | Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. |
| [2] | Gong JE, Kim JE, Lee SJ, et al.Anti-cancer effects of α-cubebenoate derived from Schisandra chinensis in CT26 colon cancer cells[J]. Molec, 2022, 27(3): 737. |
| [3] | 魏小成, 李成义, 贾妙婷, 等. 红芪多糖药理作用及机制的研究进展[J]. 中草药, 2023, 54(9): 2953-2961. |
| [4] | 李霞, 郭弘, 毛登烜, 等. 2种丹参酮ⅡA-黄芪甲苷共载纳米给药系统的制备及体外抗肿瘤活性比较[J]. 中国中药杂志, 2023, 48(3): 672-680. |
| [5] | Wang JY, Jiang MW, Li MY, et al.Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation[J]. J Nutr Biochem, 2022, 100: 108899. |
| [6] | Xue ZY, Shi GG, Fang YY, et al.Protective effect of polysaccharides from Radix Hedysari on gastric ulcers induced by acetic acid in rats[J]. Food Funct, 2019, 10(7): 3965-3976. |
| [7] | 李力, 郭祥翠, 王倩青, 等. 红芪多糖对卵巢癌SKOV3细胞凋亡、生长和运动能力的影响[J]. 天津医药, 2021, 49(5): 455-459. |
| [8] | 蒋鸿晶, 仲国庆, 张洋. 红芪多糖介导STAT3通路抑制卵巢癌小鼠肿瘤细胞免疫逃逸 [J]. 免疫学杂志, 2023, 39(3): 233-239+247. |
| [9] | Wei DF, Wei YX, Zhang LF, et al.Sulfated modification, characterization and antitumor activities of Radix hedysari polysaccharide[J]. Int J Biol Macromol, 2012,51(4): 471-476. |
| [10] | Du XL, Zhao YJ, Ma YQ, et al.Effect of radix hedysari polysaccharide on glioma by cell cycle arrest and TNF-α signaling pathway regulation[J]. Int J Poly Sci, 2019, 2019(1): 1-7. |
| [11] | 杜亚青, 李向英, 张丽晓, 等. 毛蕊异黄酮抑制胃癌干细胞样细胞的增殖、迁移与侵袭并诱导凋亡[J]. 中国病理生理杂志, 2023, 39(1): 37-44. |
| [12] | 周立霞, 吴月明, 李娜, 等. 毛蕊异黄酮增强顺铂对胃癌细胞增殖的抑制作用[J]. 中国医科大学学报, 2017, 46(1): 50-54. |
| [13] | Zhang Y, Zhang JQ, Zhang T, et al.Calycosin induces gastric cancer cell apoptosis via the ros-mediated MAPK/STAT3/NF-κB pathway[J]. Onco Targe Ther, 2021, 14: 2505-2517. |
| [14] | 王维, 张路阳, 赵子龙, 等. 毛蕊异黄酮抑制胶质瘤细胞增殖的机制研究 [J]. 沈阳药科大学学报, 2020, 37(8): 725-729+755. |
| [15] | Nie XH, Zhou Y, Li XB, et al.Calycosin down-regulates c-Met to suppress development of glioblastomas[J]. J Biosci, 2019, 44(4): 96. |
| [16] | 谭雄, 陈洁, 熊国祚, 等. 毛蕊异黄酮通过Nrf2/HO-1信号途径诱导人甲状腺癌FTC-133细胞发生铁死亡[J]. 现代肿瘤医学, 2022, 30(18): 3269-3274. |
| [17] | Qu N, Jun S, Huang N, et al.Calycosin induces autophagy and apoptosis via Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells[J]. Front in Pharmac, 2022, 16: 1-11. |
| [18] | 孙腾飞, 李俊峰, 陶方方, 等. 毛蕊异黄酮干预Hippo通路抑制三阴性乳腺癌MDA-MB-231细胞增殖与迁移的机制[J]. 中国药理学通报, 2022, 38(10): 1517-1523. |
| [19] | 周立霞, 关洪全, 王淳, 等. 毛蕊异黄酮抑制肺腺癌细胞增殖和迁移的miR-21/PTEN信号通路机制研究[J]. 中国药房, 2019, 30(12): 1595-1602. |
| [20] | 牛永莉, 贾晓波, 王艳. 芒柄花素调控miR-19b-3p/TGF-β/Smad2信号通路影响卵巢癌细胞的增殖、迁移、侵袭和凋亡[J]. 沈阳药科大学学报, 2021, 38(10): 1068-1075. |
| [21] | 古彩茹, 林梦园, 刘威. 芒柄花黄素对体外卵巢癌细胞活力、迁移与侵袭的影响[J]. 中国病理生理杂志, 2020, 36(8): 1434-1438. |
| [22] | 李自全, 孟祥娇. 芒柄花素对人非小细胞肺癌细胞增殖、凋亡的影响及相关机制探讨[J]. 中国实验方剂学杂志, 2016, 22(20): 138-142. |
| [23] | 高咏梅, 仵妍, 徐晖, 等. 芒柄花黄素对宫颈癌细胞放疗敏感性的影响[J]. 中国老年学杂志, 2019, 39(16): 4066-4069. |
| [24] | 董陈诚, 钟漓, 张广钰, 等. 芒柄花黄素对人胃癌细胞MKN-45荷瘤裸鼠模型的抑制作用及机制研究 [J]. 重庆医学, 2016, 45(32): 4482-4483+4486. |
| [25] | 顾万, 邹穗怡. 芒柄花黄素对HEC-1A荷瘤裸鼠的抗肿瘤作用[J]. 广东医学, 2014, 35(8): 1167-1170. |
| [26] | Chen J, Zhao X, Ye Y, et al.Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin[J]. Cell Physiol Biochem, 2013, 32(6): 1790-1797. |
| [27] | Wu Y, Zhang X, Li Z, et al.Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of miR-21 and PTEN[J]. Food Funct, 2017, 8(3): 1061-1066. |
| [28] | 焦文鹏, 焦文静, 张金艳. 刺芒柄花素通过COX-2/cyclin D1轴调控肝癌的发生和发展[J]. 中国肿瘤生物治疗杂志, 2021, 28(9): 877-884. |
| [29] | Hu W, Wu X, Tang J, et al.Anti-cancer targets of formononetin and molecular mechanisms in osteosarcoma:findings of bioinformatic and experimental assays[J]. J Cell Mol Med, 2019, 23(5): 3505-3511. |
| [30] | Liu Y, He J, Chen X, et al.The proapoptotic effect of formononetin in human osteosarcoma cells:involvement of inactivation of ERK and Akt pathways[J]. Cell Physiol Biochem, 2014, 34(3): 637-645. |
| [31] | Kim C, Lee SG, Yang WM, et al.Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model[J]. Cancer Lett, 2018, 431: 123-141. |
| [32] | Wang AL, Li Y, Zhao Q, et al.Formononetin inhibits colon carcinoma cell growth and invasion by microRNA-149-mediated EphB3 downregulation and inhibition of PI3K/Akt and STAT3 signaling pathways[J]. Mol Med Rep, 2018, 17(6): 7721-7729. |
| [33] | Li T, Zhao X, Mo Z, et al.Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells[J]. Cell Physiol Biochem, 2014, 34(4): 1351-1358. |
| [34] | 厉婷, 李亮亮, 黄金智, 等. 毛蕊异黄酮苷对卵巢上皮性肿瘤细胞的增殖和凋亡的影响及作用机制[J]. 中国妇产科临床杂志, 2021, 22(6): 639-642. |
| [35] | 张冬梅. 毛蕊异黄酮-7-O-β-D-葡萄糖苷对人宫颈癌HeLa细胞凋亡及Bcl-2/Bax表达的影响[J]. 中草药, 2015, 46(10): 1498-1502. |
| [36] | 祝珊珊, 余惟一, 毕丽伟, 等. 槲皮素通过激活PTEN抑制PI3K/AKT及JNK信号通路诱导人乳腺癌细胞凋亡[J]. 细胞与分子免疫学杂志, 2022, 38(8): 714-720. |
| [37] | 邵延萱, 罗文哲, 张辉. 槲皮素调控p53表达对胃癌细胞恶性行为的作用[J]. 中国老年学杂志, 2021, 41(21): 4803-4806. |
| [38] | 脱淑梅, 张彦骅, 党云, 等. 槲皮素对子宫颈癌荷瘤小鼠移植瘤生长的影响及其机制 [J]. 中国临床药理学杂志, 2021, 37(2): 150-152+156. |
| [39] | 向秋玲, 李雪兰, 黄薇霖, 等. 槲皮素通过G3BP1调控Wnt信号通路抑制宫颈癌细胞增殖[J]. 中药药理与临床, 2020, 36(4): 102-108. |
| [40] | 徐亚文, 邹丽芳, 李菲. 槲皮素对多发性骨髓瘤的抗肿瘤作用及其相关机制[J]. 中国实验血液学杂志, 2020, 28(4): 1234-1239. |
| [41] | Mondal M, Hossen MS, Rahman MA, et al.Antioxidant mediated protective effect of Bridelia tomentosa leaf extract against carbofuran induced oxidative hepatic toxicity[J]. Toxicol Rep, 2021, 8: 1369-1380. |
| [42] | 杨锋, 姜涛, 张利宏, 等. 柚皮苷通过阻断JAK/STAT信号通路抑制Eca109人食管癌细胞的增殖、侵袭并促进其凋亡[J]. 细胞与分子免疫学杂志, 2021, 37(12): 1085-1091. |
| [43] | Raha S, Kim SM, Lee HJ, et al.Naringin induces lysosomal permeabilization and autophagy cell death in AGS gastric cancer cells[J]. Am J Chin Med, 2020,48(3): 679-702. |
| [44] | 陈晨, 王浩渊. 中药组方红芪、炒薏苡仁联合美沙拉嗪栓对宫颈癌根治性放疗后放射性肠炎的预防作用[J]. 中国现代药物应用, 2022, 16(8): 167-169. |
| [45] | 窦春江, 寇炜, 李应东, 等. 当归红芪超滤物联合重离子12C6+对肝癌H22细胞辐射增敏的实验研究 [J]. 四川大学学报(医学版), 2017, 48(6): 840-843+861. |
| [46] | 董玉梅, 王小虎, 寇炜, 等. 红芪多糖联合X线对HepG-2细胞DNA损伤的影响[J]. 实用肿瘤杂志, 2012, 27(4): 344-349. |
| [47] | 王玥, 段惠春. 当归、红芪提取物对人肝癌SMMC-7721细胞辐射增敏作用 [J]. 甘肃医药, 2023, 42(6): 485-488+496. |
| [48] | 寇炜, 马卫红, 岳一平, 等. 当归红芪超滤物对TM40D人乳腺癌荷瘤小鼠的放射增敏作用[J]. 中医杂志, 2014, 55(3): 242-245. |
| [1] | Yuanyuan HUANG, Lingzhun WANG. Research progress in the intervention of myocardial fibrosis by regulating signal pathways with traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 372-381. |
| [2] | Jianqiang DU, Qi ZHANG, Enpeng GU, Chen XU, Yuan GUO, Menglong ZHANG, Jinke GUO, Si WU, Haibo XIE. Advances in the modulation of Nrf2 signaling by natural compounds for the treatment of intervertebral disc degeneration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 116-124. |
| [3] | SONG Cong, GAO Jinglin, BAN Feng, MENG Meng, WANG Mingxia. Research progress of PARP inhibitors in the treatment of brain glioma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1281-1289. |
| [4] |
LI Shanshan, WEI Dandan, KANG Hanyu, LIU Xiaopeng, YAN Shuxun, JIANG Shiqing.
Research progress on the clinical application and mechanism of commonly used traditional Chinese medicine in the treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 977-983.
|
| [5] | DU Lijuan, LIN Jianhua, YE Jinghuan, SONG Lu, PENG Yanfen, LIU Yuping. Effect and mechanism of Yiqi tongfu xiere prescription on lipopolysaccharide-induced acute lung injury in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(5): 599-607. |
| [6] | CAO Jun, ZHOU Yanlin, AI Zhengwen, LI Shigang. Research progress on mechanism of action of Chaenomeles speciosa Nakai in the treatment of rheumatoid arthritis bone restruction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 404-411. |
| [7] | SUN Jianing, WANG Ruiqi, YANG Weidong, ZHANG Lu, WANG Yan, CHENG Yangang, WANG Yingli, HAO Xuliang. Exploring the mechanism of Bai-lian turbidity reducing formula in treating lipid metabolism disorders based on transcriptomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(12): 1658-1668. |
| [8] | HUANG Shumin, XIE Baocheng, LIU Guohui. Research progress on the mechanism of GLP-1 receptor agonists in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(12): 1701-1710. |
| [9] | LUO Jiawei, CHEN Tianwang, WANG Xinyu, LIU Juan, HUANG Bo, LI Lisheng, XU Shangfu. Research progress on the effect and mechanism of natural products of traditional Chinese medicine in preventing vascular restenosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(10): 1408-1416. |
| [10] | Celimuge, Hudeligen, XU Liang. Network pharmacology-molecular docking analysis and experimental validation to explore the protective mechanism of Mongolian medicine Gaoyou on renal function [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(9): 968-978. |
| [11] | PANG Lili, HU Ying, LUO Jie, TU Qin, CHEN Min. Study of the mechanism of combretastatin a-4 derivative LGD5 induced G2/M cycle arrest and apoptosis in human cervical cancer HeLa cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(10): 1100-1109. |
| [12] | YAN Xiaoting, WANG Xinye, BAI Ming, YAO Guodong. Research progress on anti-glioma mechanism of natural sesquiterpene lactones [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(10): 1174-1184. |
| [13] | XU Jinhui, YUE Hongmei, LI Yating, LIU Miaomiao, WU Xingdong, ZHU Haobin. Advances in the study of mesenchymal stem cells in obstructive sleep apnea hypoventilation syndrome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(1): 114-120. |
| [14] | LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340. |
| [15] | CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||